NewAmsterdam Pharma Company NV
NAMS37.000USD
-0.950-2.50%
收盤 11/03, 16:00（美東）報價延遲15分鐘
4.16B總市值
虧損本益比TTM
關於 NewAmsterdam Pharma Company NV 公司
NewAmsterdam Pharma Company NV 是一家荷蘭公司。NewAmsterdam Pharma 是一家臨牀階段公司，專注於研究和開發用於治療主要心臟代謝疾病的變革性口服療法。該公司正在研究 obicetrapib，一種口服、低劑量、每日一次的膽固醇酯轉移蛋白 (CETP) 抑制劑，作爲低密度脂蛋白膽固醇 (LDL-C) 降低療法，用作高風險心血管疾病 (CVD) 患者的輔助他汀類藥物療法。該公司還在第二階段 2 期試驗 ROSE2 中測試 obicetrapib 與依折麥布的固定劑量聯合療法，用於治療阿爾茨海默病等其他疾病。該公司致力於在全球範圍內提供其產品。
NewAmsterdam Pharma Company NV簡介
公司代碼NAMS
公司名稱NewAmsterdam Pharma Company NV
上市日期Nov 23, 2022
CEODr. Michael Harvey Davidson, M.D.
員工數量68
證券類型Ordinary Share
年結日Nov 23
公司地址Gooimeer 2-35
城市NAARDEN
上市交易所NASDAQ Global Market Consolidated
國家Netherlands
郵編1411 DC
電話31352062971
網址https://ir.newamsterdampharma.com/
公司代碼NAMS
上市日期Nov 23, 2022
CEODr. Michael Harvey Davidson, M.D.
NewAmsterdam Pharma Company NV公司高管
名稱
名稱/職務
職務
持股
持股變動
Mr. Mark C. Mckenna
Mr. Mark C. Mckenna
Independent Director
Independent Director
6.96K
--
Mr. Wouter Joustra
Mr. Wouter Joustra
Independent Director
Independent Director
--
--
Dr. Michael Harvey Davidson, M.D.
Dr. Michael Harvey Davidson, M.D.
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
--
--
Mr. William H. (Will) Lewis, J.D.
Mr. William H. (Will) Lewis, J.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
-100.00%
Ms. Louise Kooij
Ms. Louise Kooij
Interim Chief Financial Officer
Interim Chief Financial Officer
--
--
Ms. Adele M. Gulfo
Ms. Adele M. Gulfo
Independent Director
Independent Director
--
--
Dr. Louis Lange, M.D., Ph.D.
Dr. Louis Lange, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Marc Ditmarsch, M.D.
Dr. Marc Ditmarsch, M.D.
Chief Development Officer
Chief Development Officer
--
--
Dr. James N. Topper, M.D., Ph.D.
Dr. James N. Topper, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Douglas Kling
Mr. Douglas Kling
Chief Operating Officer
Chief Operating Officer
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Mr. Mark C. Mckenna
Mr. Mark C. Mckenna
Independent Director
Independent Director
6.96K
--
Mr. Wouter Joustra
Mr. Wouter Joustra
Independent Director
Independent Director
--
--
Dr. Michael Harvey Davidson, M.D.
Dr. Michael Harvey Davidson, M.D.
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
--
--
Mr. William H. (Will) Lewis, J.D.
Mr. William H. (Will) Lewis, J.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
-100.00%
Ms. Louise Kooij
Ms. Louise Kooij
Interim Chief Financial Officer
Interim Chief Financial Officer
--
--
Ms. Adele M. Gulfo
Ms. Adele M. Gulfo
Independent Director
Independent Director
--
--
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 13 小時前
更新時間: 13 小時前
持股股東
股東類型
持股股東
持股股東
佔比
Frazier Life Sciences Management, L.P.
14.76%
Bain Capital Life Sciences Investors, LLC
9.52%
RA Capital Management, LP
9.00%
Forbion Capital Partners
8.27%
Capital World Investors
7.45%
其他
51.00%
持股股東
持股股東
佔比
Frazier Life Sciences Management, L.P.
14.76%
Bain Capital Life Sciences Investors, LLC
9.52%
RA Capital Management, LP
9.00%
Forbion Capital Partners
8.27%
Capital World Investors
7.45%
其他
51.00%
股東類型
持股股東
佔比
Investment Advisor
29.22%
Investment Advisor/Hedge Fund
24.29%
Venture Capital
20.51%
Hedge Fund
15.00%
Private Equity
14.76%
Research Firm
1.68%
Family Office
0.74%
Sovereign Wealth Fund
0.44%
Individual Investor
0.44%
機構持股
更新時間: 10月1日 週三
更新時間: 10月1日 週三
報告期間
機構數
持股數
持股佔比
持股變動
2025Q3
280
119.62M
106.21%
+3.10M
2025Q2
263
127.89M
114.87%
+4.67M
2025Q1
255
126.71M
112.87%
+7.17M
2024Q4
216
108.34M
98.72%
+13.96M
2024Q3
194
82.73M
88.90%
-12.05M
2024Q2
184
81.92M
90.19%
-12.22M
2024Q1
155
81.92M
90.50%
-4.21M
2023Q4
117
72.34M
86.57%
-9.73M
2023Q3
116
71.44M
85.50%
-13.42M
2023Q2
109
71.10M
86.48%
+7.09M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Frazier Life Sciences Management, L.P.
16.63M
14.76%
+18.71K
+0.11%
Aug 18, 2025
Bain Capital Life Sciences Investors, LLC
10.72M
9.52%
--
--
Jun 30, 2025
RA Capital Management, LP
10.14M
9%
--
--
Jun 30, 2025
Forbion Capital Partners
9.32M
8.27%
-1.26M
-11.93%
Sep 26, 2025
Capital World Investors
8.39M
7.45%
+1.59M
+23.37%
Jun 30, 2025
Viking Global Investors LP
6.98M
6.2%
--
--
Jun 30, 2025
Deerfield Management Company, L.P.
5.12M
4.54%
+1.01M
+24.66%
Jun 30, 2025
Jennison Associates LLC
2.95M
2.62%
-1.02M
-25.79%
Jun 30, 2025
Wellington Management Company, LLP
3.32M
2.95%
-218.98K
-6.18%
Jun 30, 2025
Adage Capital Management, L.P.
3.01M
2.68%
+1.06M
+54.46%
Jun 30, 2025
查看更多
持股ETF
更新時間: 11月2日 週日
更新時間: 11月2日 週日
機構名稱
佔比
ALPS Medical Breakthroughs ETF
1.94%
Global X Guru Index ETF
1.39%
Virtus LifeSci Biotech Clinical Trials ETF
0.98%
First Trust NASDAQ Pharmaceuticals ETF
0.59%
Harbor Health Care ETF
0.55%
Invesco Dorsey Wright SmallCap Momentum ETF
0.41%
ProShares Ultra Nasdaq Biotechnology
0.33%
Invesco Nasdaq Biotechnology ETF
0.32%
iShares Biotechnology ETF
0.2%
First Trust IPOX Europe Equity Opportunities ETF
0.15%
查看更多
ALPS Medical Breakthroughs ETF
佔比1.94%
Global X Guru Index ETF
佔比1.39%
Virtus LifeSci Biotech Clinical Trials ETF
佔比0.98%
First Trust NASDAQ Pharmaceuticals ETF
佔比0.59%
Harbor Health Care ETF
佔比0.55%
Invesco Dorsey Wright SmallCap Momentum ETF
佔比0.41%
ProShares Ultra Nasdaq Biotechnology
佔比0.33%
Invesco Nasdaq Biotechnology ETF
佔比0.32%
iShares Biotechnology ETF
佔比0.2%
First Trust IPOX Europe Equity Opportunities ETF
佔比0.15%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
